Last updated on April 24, 2014 at 17:35 EDT

Sirius Genomics Launches Major International Sepsis Study

October 11, 2011

Eight Centers in North America and Europe Participate in a Search for

VANCOUVER, Oct. 11, 2011 /PRNewswire/ – BC-based biotech company Sirius
Genomics today announced the launch of a large, international study
that enlists the help of some of the world’s top acute care centers in
a hunt for a biomarker that would predict outcome from a controversial
treatment using activated protein C.

With an estimated 18 million global cases annually, sepsis is associated
with high mortality rates at between 30 percent and 50 percent, and
patients are three times more likely to die from sepsis as from heart
attack. In the past 20 years, only one drug, activated protein C, has
been approved for use in sepsis treatment. The problem is that while
activated protein C can be highly effective, it can also have adverse
side effects so doctors are reluctant to prescribe it.

“This study is unique because we have attracted the top clinical
researchers in the world to participate,” said Chris Wagner, President
and CEO at Sirius Genomics. “Our common goal is to determine whether
there is a genetic marker for positive response to treatment with
activated protein C. Doctors can then run a simple test before
prescribing the drug to ensure a patient with sepsis will benefit from

“For critical care physicians treating severe sepsis, activated protein
C offers significant benefit, increasing overall patient survival by
approximately 13 percent,” said Dr. Jim Russell, Professor of Medicine
at the University of British Columbia and Co-founder at Sirius. “Its
use is limited by the difficulty of distinguishing those patients who
would most benefit from those who may face adverse side effects
from activated protein C. A statistically significant genetic biomarker
to identify which patients benefit most would virtually eliminate this
uncertainty and help save lives.”

About Sirius Genomics
A private biotechnology company based in Vancouver, Canada, Sirius
Genomics develops companion diagnostics (CDx) that are closely tied to
therapeutic decisions, leading to better patient outcomes through
personalized medicine. Sirius generates value by improving the safety
and effectiveness of pharmaceutical compounds. The Company correlates
patient genetics with clinical outcomes, leading to proprietary and
commercially viable CDx products that enable better drug treatment. The
Company’s lead product is a genetic predictor of response to treatment
for sepsis, a deadly syndrome that worldwide impacts 18 million people

SOURCE Sirius Genomics Inc.

Source: PR Newswire